Apotea AB (publ) (STO:APOTEA)
Sweden
· Delayed Price · Currency is SEK 101.54
+1.40 (1.40%)
At close: May 12, 2025
Apotea AB Revenue
In the year 2024, Apotea AB had annual revenue of 6.55B SEK with 20.01% growth. Apotea AB had revenue of 1.74B in the quarter ending December 31, 2024.
Revenue
6.55B
Revenue Growth
+20.01%
P/S Ratio
1.56
Revenue / Employee
8.47M
Employees
800
Market Cap
10.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.55B | 1.09B | 20.01% |
| Dec 31, 2023 | 5.46B | 572.40M | 11.72% |
| Dec 31, 2022 | 4.88B | 303.30M | 6.62% |
| Dec 31, 2021 | 4.58B | 1.74B | 61.34% |
| Dec 1, 2019 | 2.84B | 746.02M | 35.65% |
| Dec 1, 2018 | Pro | Pro | Pro |
| Dec 1, 2017 | Pro | Pro | Pro |
| Dec 1, 2016 | Pro | Pro | Pro |
| Dec 1, 2015 | Pro | Pro | Pro |
| Dec 1, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Camurus AB | 1.87B |
| Medicover AB | 23.56B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Vimian Group AB | 4.24B |